A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Tamibarotene (Primary) ; Azacitidine; Azacitidine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Biomarker; Proof of concept; Therapeutic Use
- Sponsors Syros Pharmaceuticals
- 08 Nov 2017 According to a company media release, Syros has recently amended the protocol of this trial to add a cohort evaluating the safety and efficacy of SY-1425 in combination with an anti-CD38 therapy in patients with relapsed or refractory AML or higher-risk MDS. The Company expects to begin enrolling patients in this cohort in early 2018. All patients enrolled or to be enrolled in the trial are prospectively selected using the Company's RARA and IRF8 biomarkers.
- 01 Nov 2017 According to a Syros Pharmaceuticals media release, data of SY-1425 in combination with azacitidine and with an anti-CD38 antibody is expected in 2018.
- 01 Nov 2017 According to a Syros Pharmaceuticals media release, initial data of SY-1425 as a monotherapy from the relapsed or refractory AML and higher-risk MDS cohort, as well as the lower-risk transfusion-dependent MDS cohort will be presented at the American Society of Hematology (ASH) 2017 Annual Meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History